Equities research analysts predict that Abeona Therapeutics Inc. (NASDAQ:ABEO) will report $230,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Abeona Therapeutics’ earnings, with the highest sales estimate coming in at $280,000.00 and the lowest estimate coming in at $200,000.00. Abeona Therapeutics posted sales of $260,000.00 in the same quarter last year, which would indicate a negative year over year growth rate of 11.5%. The company is scheduled to announce its next earnings results on Friday, March 30th.

On average, analysts expect that Abeona Therapeutics will report full-year sales of $230,000.00 for the current fiscal year, with estimates ranging from $800,000.00 to $930,000.00. For the next fiscal year, analysts anticipate that the business will post sales of $1.14 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million.

Several equities research analysts have issued reports on ABEO shares. Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. HC Wainwright restated a “buy” rating and issued a $30.00 price target (up from $20.00) on shares of Abeona Therapeutics in a report on Monday, October 9th. Royal Bank Of Canada started coverage on Abeona Therapeutics in a report on Thursday, September 14th. They issued an “outperform” rating and a $23.00 price target for the company. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a report on Tuesday, August 29th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. Abeona Therapeutics presently has a consensus rating of “Buy” and an average target price of $22.90.

Shares of Abeona Therapeutics (NASDAQ:ABEO) traded down $0.65 during trading on Friday, hitting $16.10. The company’s stock had a trading volume of 723,200 shares, compared to its average volume of 623,496. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $22.75.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/17/230000-00-in-sales-expected-for-abeona-therapeutics-inc-abeo-this-quarter.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Abeona Therapeutics by 11.2% during the second quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after purchasing an additional 108,730 shares during the last quarter. State Street Corp acquired a new position in Abeona Therapeutics during the second quarter valued at approximately $1,900,000. Northern Trust Corp boosted its position in Abeona Therapeutics by 406.3% during the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 206,775 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Abeona Therapeutics during the third quarter valued at approximately $3,527,000. Finally, Wellington Management Group LLP boosted its position in Abeona Therapeutics by 17.4% during the first quarter. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company’s stock valued at $1,023,000 after purchasing an additional 30,300 shares during the last quarter. 33.36% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.